• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 25, 2020

View Archived Issues
Deal-handshake-graphic-overlay

Genentech immuno-oncology ambitions take a ride on bicyclics

Bicycle Therapeutics plc said Roche Holding AG's Genentech Inc. has agreed to pay $30 million up front for rights to develop and commercialize up to four potential immuno-oncology therapies using the company's bicyclic peptide platform. Bicycle will be responsible for all discovery and lead optimization, while Genentech will take up R&D beyond that. Read More

IMV’s phase II ovarian cancer data trend positive while the stock reverses

Updated results from IMV Inc.’s ongoing phase II trial of DPX-Survivac to treat advanced recurrent ovarian cancer show the company’s lead candidate was active and well-tolerated in patients. Read More
Acute myeloid leukemia

Advanced Biodesign advances toward the clinic with dual ALDH inhibitor

DUBLIN – Advanced Biodesign SAS secured €9 million (US$9.8 million) in new funding commitments to take its lead drug candidate, ABD-3001, into a phase I trial in acute myeloid leukemia (AML). The Lyon, France-based firm is investigating a novel drug mechanism associated with cancer cell metabolism, which could have application across several cancer types. Read More
Drug-supply-export

Administration, lawmakers weigh in as COVID-19 concerns grow in the U.S.

“The FDA is keenly aware that the outbreak will likely affect the medical product supply chain, including potential disruption to supplier shortages of critical medical products in the U.S.,” FDA Commissioner Stephen Hahn said Tuesday, Feb. 25, during a Department of Health and Human Services (HHS) briefing on the COVID-19 outbreak. Read More
Coronavirus-therapy-development

Coronavirus outbreak brings focus on companies developing potential therapies

The public attention that COVID-19 has received has spilled over to antibiotics companies, and the BioWorld Infectious Diseases index has grown 14% in value since the beginning of the year. Read More

Fujifilm stock rises as Japan considers Avigan for COVID-19 treatment

HONG KONG – Fujifilm Holdings Corp. stock (TYO:4901) jumped 8.8% to ¥5,890 (US$53.48) on Feb. 25, as Japan considers using Avigan (favipiravir), an anti-influenza medication developed by the company’s Toyama Chemical Co. Ltd., to treat COVID-19. The share price ended the day at ¥5,567, for a gain of 2.83%. Read More

Chinese biotechs apply new tech to accelerate drug R&D for COVID-19

BEIJING – As the clock ticks on COVID-19’s spread, Chinese biotech companies are hoping to unleash the power of cloud computing and artificial intelligence to find a cure for the virus. Read More

Appointments and advancements for Feb. 25, 2020

New hires and promotions in the biopharma industry, including: Adverum, Biocryst, Centogene, Epirium, Halozyme, Krystal, Neoleukin. Read More

Earnings for Feb. 25, 2020

Quarterly snapshots from biopharma companies with marketed products, including: Intercept, Insmed, Theratechnologies. Read More

Financings for Feb. 25, 2020

Biopharmas raising money in public or private financings, including: Aivita, Astrazeneca, Axovant, Kahr, Lipocine, Promis, Redhill. Read More

In the clinic for Feb. 25, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acer, Allecra, Herantis, Ico, IMV, IO Biotech, Marinus, Reneuron, Theralase. Read More

Other news to note for Feb. 25, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 1st Biotherapeutics, Arecor, Artizan, Astrazeneca, Atrin, Auris, Axovant, Certara, Daiichi Sankyo, Domainex, Dyadic, Excellerate, Immunos, In Silico, Index, Kahr, Lipocine, Lunac, Mallinckrodt, Moderna, Nektar, Omass, Oncologie, Peptilogics, Point Predictive Technology Group, Probiogen, Promis, Proteostasis, Redhill, Roche, Spring Bank, Tetra, Trianni, Twoxar, Vir, Wuxi. Read More

Regulatory actions for Feb. 25, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Genentech, Halozyme, Lysogene, Noxopharm. Read More

Regulatory front for Feb. 25, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: Actavis, Horizon, Yibin Lihao.

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe